Exosome Stem Cell Therapy for Chronic Inflammation: How It Supports Repair and Recovery

In this episode, we explore how exosome stem cell therapy supports tissue repair and helps manage chronic inflammation without using whole stem cells.

You’ll learn:

• What exosome stem cell therapy is and how it differs from traditional stem cell therapy
• How exosomes support cell communication, tissue repair, and regeneration
• Why exosome therapy may help reduce chronic inflammation and regulate immune response
• The potential benefits for joint health, autoimmune conditions, skin repair, and hair restoration
• What current research says about the safety and effectiveness of exosome therapy
• Why exosome therapy is becoming a promising option in regenerative medicine

Whether you're exploring treatment options for chronic inflammation, autoimmune conditions, or injury recovery, this episode explains how exosome stem cell therapy works and what current research says about its potential benefits.

Blog Link: How Exosome Stem Cell Therapy Supports Repair and Inflammation Control in Chronic Conditions

Transcript

SPEAKER_00 0:00

Welcome to the Saurona Cell Podcast. I am really thrilled to have you here with us for today's deep dive. We are jumping into something that, well, it honestly sounds like science fiction at first glance.

SPEAKER_01 0:11

It really does, yeah.

SPEAKER_00 0:12

Right. I mean, imagine you're trying to fix a malfunctioning car engine. But instead of sending in a mechanic with a wrench, you know, to physically replace parts, you just inject this microscopic flash drive into the fuel tank.

SPEAKER_01 0:24

Oh, that's a that is a great way to look at it.

SPEAKER_00 0:27

Yeah. And that flash drive just circulates until it finds the broken part, plugs itself in, and downloads a software update that tells the engine exactly how to repair itself.

SPEAKER_01 0:36

And that is essentially what we are talking about today.

SPEAKER_00 0:38

Exactly. It sounds crazy, but if you've been following the leading edge of regenerative medicine, you know this is rapidly becoming a clinical reality. So our mission for this deep dive is to explore how exosome stem cell therapy actually supports tissue repair and controls chronic inflammation.

SPEAKER_01 0:56

Right. And we're looking at a very specific set of clinical literature today, alongside the operational protocols from Cyrona Cell, to kind of ground this all in reality.

SPEAKER_00 1:06

Yeah, which I think is so important to see how the theory actually plays out in a real clinic.

SPEAKER_01 1:11

Absolutely. So just to give you an overview of the sources we are unpacking, they cover this massive paradigm shift from theoretical biology to applied medicine. We're going to examine the biology of cell-free vesicles, which are those exosomes you just mentioned. Right. We'll look at the actual mechanics of how they modulate chronic inflammation at a cellular level. And we are doing all of this through the lens of Sarona Cell, which is this regenerative medicine center that has built a really structured, internationally focused service model around this very science.

SPEAKER_00 1:45

And I am so excited to get into that paradigm shift. You know, this whole idea of a cell-free stem cell therapy. Yeah. Because it really takes us on a journey from the macroscopic clinic down to the microscopic biology of how we heal.

SPEAKER_01 1:57

Aaron Powell It's a huge leap. I mean, we we really should start by looking at who is actually putting this into practice before we put the science under the microscope.

SPEAKER_00 2:04

Yeah, because the field of regenerative medicine can sometimes feel like a bit of a well, kind of a frontier town, right?

SPEAKER_01 2:10

Aaron Ross Powell Oh, definitely. A lot of wild claims out there.

SPEAKER_00 2:12

Aaron Ross Powell Exactly. So the philosophy of the clinic matters immensely. And our sources point us directly to Sorona Cell, which is a doctor-led center based in Kuala Lumpur, specifically the Cyberjaya area of Malaysia. Aaron Ross Powell, Jr.

SPEAKER_01 2:25

Which is a major tech and medical hub over there.

SPEAKER_00 2:28

Aaron Ross Powell Right. And looking at their patient demographics and the materials, they have this surprisingly broad reach. Like obviously they're treating local patients, but a significant portion of their base is traveling internationally.

SPEAKER_01 2:41

Yeah, the sources note a lot of patients coming in from Australia and the Middle East specifically for this structured cell therapy.

SPEAKER_00 2:49

Aaron Powell Which is fascinating. People are getting on long-haul flights for this.

SPEAKER_01 2:53

Well, that international draw usually indicates a demand for a highly specific standard of care. You know, you don't fly across the world for something you can get safely down the street. Good point. And the branding itself actually signals their approach to that care. I found this really interesting. Sorona is actually named after a Celtic goddess associated with health and protection.

SPEAKER_00 3:11

I love that. A Celtic goddess in Malaysia, it's a really cool branding choice that perfectly frames their medical ethos.

SPEAKER_01 3:18

Yeah, because when you look at their clinical protocols, protection really is the defining theme. It's protection first, always. They operate strictly under BSL2 lab standards, that's biosafety level two, along with CGMP and ISO 9001 certifications.

SPEAKER_00 3:34

Okay, wait. I want to pause on those certifications for a second because ISO 9001 is a manufacturing quality standard, right?

SPEAKER_01 3:41

Yes, it is.

SPEAKER_00 3:42

So why is a medical clinic highlighting a manufacturing standard for a biological treatment? That feels a bit weird.

SPEAKER_01 3:48

Aaron Powell It does sound a bit industrial, but it's actually crucial because when you are dealing with cellular products, consistency is the primary challenge. And ISO 9001 certification means their laboratory isn't just uh relying on the individual skill of whoever happens to be working that day.

SPEAKER_00 4:04

Trevor Burrus Right, like hoping you get the good scientist.

SPEAKER_01 4:06

Exactly. They have standardized auditable systems in place to ensure that identity, sterility, and viability checks are identical for every single batch they produce. It eliminates the variables.

SPEAKER_00 4:16

Wow. Okay. So it's about absolute predictability in something that is inherently biological and messy.

SPEAKER_01 4:22

Precisely. And that strictness extends right down to their source material. The literature notes they use ethically sourced umbilical cord-derived cells. Specifically, they use early passage Wharton's jelly mesenchymal stem cells, or WJMSCs from healthy term deliveries.

SPEAKER_00 4:39

Okay, so if you are listening to this and you know the basics of stem cells, you might recognize MSCs. But the literature throws around terms like Wharton's jelly and early passage, which I mean, let's define those because they sound more like industry jargon than medical science. What exactly is Wharton's jelly?

SPEAKER_01 4:56

I know it's a slightly strange historical name, isn't it? But Wharton's jelly just refers to the gelatinous connective tissue found inside the umbilical cord.

SPEAKER_00 5:04

Okay.

SPEAKER_01 5:04

And it happens to be one of the richest, most robust sources of mesenchymal stem cells in the human body.

SPEAKER_00 5:09

Aaron Powell So they aren't extracting this from the patient's own fat or bone marrow.

SPEAKER_01 5:14

No, because umbilical cord cells are basically brand new. They are at day zero of aging. And that brings us to the term early passage, which is so critical for safety.

SPEAKER_00 5:22

Right. Explain that, because I saw that highlighted several times.

SPEAKER_01 5:26

So when labs culture stem cells, they multiply them. And each time they multiply and are transferred to a new culture flask, it's called a passage.

SPEAKER_00 5:34

Kind of like copying a file.

SPEAKER_01 5:35

Perfect analogy, yeah. If you passage cells too many times, just like making a copy of a copy of a copy, they can begin to degrade or experience genetic drift. Cirona cell restricts their cultures to early passages, meaning the cells are as close to their vigorous original state as possible.

SPEAKER_00 5:52

Aaron Powell That makes a lot of sense. The materials also draw a very hard line on what they will not use. Like they explicitly state that they do not use embryonic stem cells, and they flat out refuse to use experimental pluripotent stem cells.

SPEAKER_01 6:06

Aaron Powell And that distinction is really where that protection first ethos materializes. I mean, climate potent stem cells have the ability to turn into literally any cell type in the human body.

SPEAKER_00 6:16

Which sounds great, right? Like why wouldn't you want the cell that can become anything?

SPEAKER_01 6:20

In theory, it sounds fantastic for regeneration. But in practice, because they are so versatile and so eager to divide, they carry a known risk of forming teratomas, which are a type of tumor.

SPEAKER_00 6:31

Oh wow. Yeah, you definitely don't want that.

SPEAKER_01 6:33

Definitely not. So by restricting their practice to mesenchymal stem cells, which are multipotent, meaning they can only differentiate into a specific limited range of tissue types like bone, cartilage, and fat, they bypass that uncontrolled growth risk entirely.

SPEAKER_00 6:48

Okay, so we have established this highly controlled, measured environment in Malaysia. They have these robust early passage MSCs. But the truly fascinating twist in the literature is that for this specific therapy, they aren't even injecting those cells.

SPEAKER_01 7:05

They aren't.

SPEAKER_00 7:06

They are using a cell-free approach. Yeah. So let's pivot from the clinic to the cellular level and dig into the biology here. What exactly is an exosome?

SPEAKER_01 7:15

So to really grasp what an exosome is, we have to look at the scale of cellular biology. When mesenchymal stem cells are active, they secrete these tiny extracellular vesicles.

SPEAKER_00 7:24

Vesicles.

SPEAKER_01 7:25

Think of a vesicle as a microscopic biological envelope. It's made of a lipid bilayer, which is very similar to the outer membrane of our regular cell. But the scale is staggering. These exosomes matter only 30 to 150 nanometers across.

SPEAKER_00 7:41

30 to 150 nanometers. So to put that into perspective for you as you're listening, a standard red blood cell is about 7,000 to 8,000 nanometers wide.

SPEAKER_01 7:51

Right.

SPEAKER_00 7:51

So these exosomes are just a fraction of a fraction of the size of a whole cell.

SPEAKER_01 7:55

Exactly. And their size is exactly what makes them so mechanically effective. Because they are so infinitesimally small, they can diffuse through the extracellular matrix, which is the dense web of proteins surrounding all our tissues, far easier than a BULTI cell ever could.

SPEAKER_00 8:10

So they can slip through the cracks.

SPEAKER_01 8:12

Precisely. They can cross barriers that whole cells simply cannot. But here's the key These embolics are not empty. They carry a very dense, highly specific therapeutic payload.

SPEAKER_00 8:22

The flash drive from the intro.

SPEAKER_01 8:23

Yes, the flash drive. They are packed with targeted proteins, bioactive lipids, and crucial genetic material like messenger RNA and microRNA. And before any of this is used, the batches are rigorously tested. They check particle size, concentration, and absolute sterility.

SPEAKER_00 8:41

So going back to that flash drive analogy, the microRNA is essentially the software update.

SPEAKER_01 8:46

Yes.

SPEAKER_00 8:47

But I want to push back on this mechanism a bit on behalf of anyone listening who's a bit skeptical. Because the literature talks about these exosomes seeking out damaged tissue. But, you know, if I inject a billion tiny flash drives into a patient's bloodstream, they don't have a brain. They don't have a GPS navigation system. Right. How do they know they need to go to, say, a torn rotator cuff and not just float around aimlessly in the liver?

SPEAKER_01 9:10

That is a great question. The mechanism driving that is a biological process called chemotaxis.

SPEAKER_00 9:15

Chemotaxis.

SPEAKER_01 9:16

Yeah. When tissue in your body is injured or inflamed, it doesn't just sit there quietly. It releases specific chemical distress signals called pro-inflammatory cytokines.

SPEAKER_00 9:26

Like biological flare guns.

SPEAKER_01 9:27

Exactly like flare guns. Now, exosomes have specific receptor proteins on their outer lipid membrane. As they circulate through the blood, these receptors bind to those chemical distress signals. So they're essentially following this chemical trail of breadcrumbs directly to the microenvironment of the injury. We call this the homing effect.

SPEAKER_00 9:48

Wow. Okay, so they quite literally follow the smoke to find the fire.

SPEAKER_01 9:53

Yes, they do.

SPEAKER_00 9:54

But let me challenge the safety of the payload itself then. If these exosomes are arriving at injured tissue and dumping genetic instructions, this microNA directly into my existing cells, isn't there a risk of them giving the wrong instructions?

SPEAKER_01 10:07

That's a very valid concern.

SPEAKER_00 10:08

Like, how do we know they won't tell a cell to grow uncontrollably and trigger the very tumors we were trying to avoid by not using those pluripotent cells earlier?

SPEAKER_01 10:16

And that is the exact question researchers had to answer before this could ever enter clinical trials. The safeguard actually lies in the nature of the microRNA derived from mesentemal stem cells. The genetic cargo in these specific exosomes does not contain the DNA machinery required to mutate the host cell permanently.

SPEAKER_00 10:33

Oh, okay. So it's not rewriting my DNA.

SPEAKER_01 10:35

Not at all. MSC-derived microRNA functions as a temporary regulatory mechanism. It's designed by nature specifically for homeostasis, basically bringing the system back to balance. Right. It enters the damaged cell, regulates the expression of certain proteins to initiate repair, and then it just degrades. It doesn't rewrite your genome, it simply modulates the cell's current behavior. Trevor Burrus, Jr.

SPEAKER_00 11:00

Okay. That makes sense. And the literature emphasizes that this communication is a two-way street, right? Like the exosomes aren't just shouting instructions at the damaged tissue, they are part of a peracrine feedback loop.

SPEAKER_01 11:12

Aaron Powell Yes, the peracrine effect is fundamental to how this works. It's not a one-way broadcast. When exosomes arrive at the injury site, they don't just deliver cargo. You have to remember the parent stem cells they came from originally produced them in response to specific environmental cues.

SPEAKER_00 11:26

Aaron Powell So they are tailored for the job.

SPEAKER_01 11:28

Aaron Ross Powell Exactly. In a clinical setting, this means the exosomes are preconditioned with anti-inflammatory and regenerative signals. There's a 2023 review from PubMed Central featured in our sources that looked really closely at this regarding wound healing.

SPEAKER_00 11:43

Oh, right. I read that one.

SPEAKER_01 11:44

Yeah, they found that the exosomes actively bind to the patient's local cells, suppressing the aggressive inflammatory response while simultaneously upregulating the production of collagen and elastin.

SPEAKER_00 11:55

That part about collagen production was fascinating because the review notes that exosomes help with what they call tissue remodeling, which actually reduces visible scarring.

SPEAKER_01 12:04

Yeah, it does, yeah.

SPEAKER_00 12:05

But how does a microscopic vesicle change whether a cut leaves a thick, raised scar or heals smoothly? Like mechanically, what is happening?

SPEAKER_01 12:13

Well, a scar is essentially a rushed repair job by your body. When tissue is severely traumatized, the body panic builds collagen. It just lays the fibers down in a chaotic, cross-hatched pattern just to seal the wound quickly to prevent infection.

SPEAKER_00 12:26

Just slap some duct tape on it.

SPEAKER_01 12:28

Exactly. And that chaotic pattern is what we see as a raised scar. But what exosomes do is they modulate the behavior of fibroblasts. Those are the cells responsible for actually building that collagen. Okay. They signal the fibroblasts to essentially calm down, slow down slightly, and lay the collagen fibers down in a neat parallel alignment, which mimics the original uninjured tissue.

SPEAKER_00 12:51

That orchestration is just brilliant. It's so elegant for a discrete, localized wound. But the major focus of these clinical applications isn't just a cut on the arm. The literature pivots heavily into chronic systemic issues, where the body is essentially attacking itself.

SPEAKER_01 13:08

Yes, which is a much bigger challenge.

SPEAKER_00 13:10

Right. Let's look at chronic inflammation. Repairing a discrete wound is one thing, but how does this cellular communication apply to chronic systemic issues?

SPEAKER_01 13:18

So if a cut is a localized fire, chronic inflammation is a systemic smoldering that refuses to burn out. In a healthy system, acute inflammation is actually the first responder.

SPEAKER_00 13:28

Right. We need inflammation to heal initially.

SPEAKER_01 13:30

Exactly. Immune cells rush in, they clear out the debris or infection, and then they leave. But in chronic conditions, the immune system loses its off-switch. Macrophages and T cells stay activated, pumping out caustic chemicals that wear down healthy tissue faster than those fibroblasts can repair it.

SPEAKER_00 13:48

And the sources make a crucial distinction here between adjusting the immune response versus suppressing it.

SPEAKER_01 13:55

Yes, that is a vital distinction.

SPEAKER_00 13:57

Because if you're dealing with a severe autoimmune issue, traditional heavy medications often suppress the entire immune system.

SPEAKER_01 14:04

Which leaves the patient incredibly vulnerable.

SPEAKER_00 14:06

Right. It's the equivalent of cutting the main power to your entire house. Yeah. Because the smoke alarm in the hallway is ringing too loudly. Yes, the alarm shuts up, but now the fridge is off, you're sitting in the dark, and you are incredibly vulnerable to, you know, a simple cold or infection.

SPEAKER_01 14:21

That's a perfect analogy.

SPEAKER_00 14:22

But the exosome approach aims to just reset the specific smoke alarm. How do they mechanically achieve that localized reset without turning off the whole immune system?

SPEAKER_01 14:33

They do it through a mechanism called macrophage polarization.

SPEAKER_00 14:36

Okay, what does that mean?

SPEAKER_01 14:37

Well, macrophages are the heavy infantry of the immune system. They typically exist in two states. You have M1, which is aggressive and highly inflammatory, and M2, which is anti-inflammatory and focused on tissue cleanup and repair.

SPEAKER_00 14:51

So M1 breaks down, M2 rebuilds.

SPEAKER_01 14:55

Precisely. In a chronic autoimmune condition like rheumatoid arthritis, for example, the joint is packed with M1 macrophages stuck in attack mode.

SPEAKER_00 15:04

Just constantly causing damage.

SPEAKER_01 15:06

Right. But when exosomes arrive, their microRNA cargo physically binds inside those macrophages and forces them to switch from the M1 phase to the M2 phase.

SPEAKER_00 15:16

Wait, so they are literally flipping a switch on the immune cells from destroy to rebuild?

SPEAKER_01 15:21

Literally. They downregulate the production of pro-inflammatory cytokines and upregulate anti-inflammatory proteins. So you aren't wiping out the patient's immune system at all. You are re-educating the immune cells that are already localized at the site of the damage. There's a 2024 review provided in the materials that tracks this exact mechanism across several inflammatory disorders. They observed significant tissue preservation in severe joint conditions, as well as complex bowel and skin disorders, purely through this localized immune modulation.

SPEAKER_00 15:53

See, listening to this, the cell-free approach just sounds vastly superior. Yeah. I mean, there is virtually no risk of immune rejection because there are no living cells with foreign surface markers. Right. There's no risk of uncontrolled cellular growth. It actively modulates inflammation without systemic suppression, which raises an obvious question, right?

SPEAKER_01 16:15

I think I know what you're going to ask.

SPEAKER_00 16:16

Why does the medical community use traditional stem cell therapy at all anymore? Like why hasn't this replaced the injection of living cells entirely?

SPEAKER_01 16:23

It's a fair question, but it comes down to the fact that signaling is only half of the regenerative equation. Think of exosomes as the architects and the foreman managing a construction site. They have the blueprints, they give the orders. But if the tissue loss is severe enough, say massive cartilage degradation in a bone-on-bone knee joint, you don't just need instructions. You need raw materials.

SPEAKER_00 16:45

Right, you need the bricks.

SPEAKER_01 16:47

Exactly. Traditional stem cell therapy provides engraftment. The living cells take up residence, they differentiate, and they physically replace the lost tissue volume. Exosomes cannot build physical structure on their own. They rely entirely on the host's existing cells to do the building.

SPEAKER_00 17:04

Ah. Okay. So if the host tissue is too far gone, there literally aren't enough local workers left to receive the flash dries instructions.

SPEAKER_01 17:12

Exactly the case. And this is why advanced clinical protocols like those utilized by specialized centers often employ a combined approach.

SPEAKER_00 17:20

Well, they use both?

SPEAKER_01 17:21

Yes. A medical team will use whole living mesenchymal stem cells to provide the necessary cellular bulk and structural repair in a severely degraded area. But simultaneously, they administer exosome therapy to provide ongoing, targeted signaling.

SPEAKER_00 17:35

To kind of calm the environment down.

SPEAKER_01 17:36

Right, to control the hostile inflammatory environment so those new cells can actually survive and integrate without being attacked.

SPEAKER_00 17:44

That makes total sense. Because they don't require keeping fragile cells alive, they are incredibly stable for storage and shipping.

SPEAKER_01 17:57

Oh, the logistics are a game changer.

SPEAKER_00 17:59

Right. For a clinic like Sorona Cell that services international patients, you're essentially shipping biological pharmaceuticals rather than living organs. You don't have to worry about the cells dying in transit.

SPEAKER_01 18:10

That logistical stability is a massive leap forward for standardizing care globally. It allows clinics to maintain rigorous quality control from the laboratory freezer all the way to the administration room. You completely avoid the degradation that plagues live cell transport.

SPEAKER_00 18:27

It's amazing. I mean, you can ship biological text messages across the world to international patients much easier than living cells.

SPEAKER_01 18:33

Exactly. But we have spent a lot of time on the biological elegance of this therapy, and I think we need to run this through a reality check.

SPEAKER_00 18:40

Yes, definitely. To stay true to Zironacell's ethos of honesty and clear explanations over exaggerated claims, we have to look at what the current data actually promises versus what is still being studied. Because if you search the internet, you will find clinics promising that exosomes cure literally everything from aging to severe neurological diseases.

SPEAKER_01 19:02

And that's where the clinical reality requires strict expectation management. The most robust, irrefutable evidence base right now exists for orthopedic joint problems, localized bowel disorders, and dermatology.

SPEAKER_00 19:14

Dermatology, like what kind of things?

SPEAKER_01 19:16

Specifically burn recovery, severe scarring, and hair follicle stimulation in alopecia.

SPEAKER_00 19:21

Right, cosmetic recovery.

SPEAKER_01 19:22

Yes. And the reason is that these tissues are highly accessible and rely heavily on the exact collagen remodeling and inflammatory modulation we discussed earlier.

SPEAKER_00 19:30

But the sources do highlight that human trials are expanding into more complex systemic diseases, right? Right. Like they specifically mention ongoing research into multiple sclerosis and chronic non-healing diabetic wounds.

SPEAKER_01 19:42

They do. The expansion into human trials for neurodegenerative diseases like multiple sclerosis is happening, and the early safety profiles are excellent.

SPEAKER_00 19:51

Okay, that's promising.

SPEAKER_01 19:52

It is, but we must read the data objectively. Much of the published literature demonstrating dramatic disease reversal still originates from laboratory environments and animal models.

SPEAKER_00 20:02

Oh, I see.

SPEAKER_01 20:03

Yeah, the human trials for these complex conditions currently feature relatively small sample sizes, and the follow-up periods are just not yet long enough to declare definitive long-term efficacy.

SPEAKER_00 20:14

Right, so we shouldn't get ahead of the science.

SPEAKER_01 20:16

Exactly. And that aligns perfectly with the clinical stance Cyreno Cell takes in the materials. They are adamant that regenerative medicine must be positioned as an adjunct therapy. It is a supportive treatment.

SPEAKER_00 20:28

So to give you the bottom line, listening at home, is this a guaranteed fix?

SPEAKER_01 20:32

No, it is not a magical replacement for your primary specialist care. It doesn't replace targeted pharmaceuticals for acute disease. And it certainly does not replace structural surgery when a joint is mechanically beyond repair.

SPEAKER_00 20:45

Because medical transparency dictates acknowledging limitations.

SPEAKER_01 20:49

Exactly. If a joint is completely devoid of cartilage and the bone architecture is collapsing, injecting exosomes will modulate the pain and inflammation temporarily, but it will not regrow a new joint from nothing. The ethical application of this therapy requires a comprehensive medical review to determine if the patient's specific biology has enough latent regenerative capacity left to even respond to the signals the exosomes are delivering.

SPEAKER_00 21:17

Right. It's about whether your body still has the capacity to read and execute the software update.

SPEAKER_01 21:22

Precisely. Individual results will always vary widely based on that.

SPEAKER_00 21:26

So synthesizing all of this, we are really looking at a profound shift in how medicine views healing. We are moving away from just, you know, cutting out the bad tissue or chemically suppressing the whole system. And we're moving toward harnessing the body's own microscopic communication network.

SPEAKER_01 21:41

It's a completely different paradigm.

SPEAKER_00 21:43

And it seems clinics like Sarona Cell in Malaysia are setting the baseline for how this should be done safely. You know, ethically sourced early passage MSEs, processed under strict manufacturing standards, all to isolate these 30 nanometer biological flash drives.

SPEAKER_01 21:58

And then sending those messengers to adjust inflammation rather than just blindly suppressing it?

SPEAKER_00 22:02

Exactly. They travel directly to the site of injury to re-educate overactive immune cells and orchestrate organized scar-free repair. It's just incredible.

SPEAKER_01 22:12

It really is. The mechanics of it challenge our basic understanding of biology. I mean, when you consider that our own cells are constantly utilizing this precise method, secreting microscopic vesicles filled with genetic instructions to coordinate immune responses and tissue repair across the body, it leaves us with a pretty compelling thought.

SPEAKER_00 22:29

Yeah. What's that?

SPEAKER_01 22:31

Well, if our own cells are constantly communicating via these microscopic cargo ships to coordinate complex tasks like wound healing and immune modulation, what other messages are our bodies sending right now that we just haven't learned how to read or harness yet?

SPEAKER_00 22:46

Oh wow, what a thought. That is the perfect question to leave hanging in the air. Thank you to you, our listener, for joining us on this deep dive into the microscopic world of exosm therapy and cellular communication. We hope unpacking the biology behind the headlines has given you a clearer, more critical lens to view the future of regenerative medicine. Keep questioning the science, and we'll see you on the next deep dive.